Hypoactive Sexual Desire Disorder (HSDD) in Postmenopausal Women
- November 16, 2017
The purpose of this study is to confirm the effectiveness of daily intravaginal administration of an prasterone for 28 weeks on Hypoactive Sexual Desire Disorder in postmenopausal women, as compared to a placebo.
Duration: Approximately 8 months
Number of visits to CKRA: Up to 6
Compensation: Up to $425 for time and travel
Note: Qualified participants must be postmenopausal women between the ages of 40 and 80 years of age whose HSDD is not the result of any acute or chronic life stress, major life change, sexual trauma or abuse, or medical disease or disorder. Other criteria also apply.